Arcutis Taps Simone Biles for Skin Disease Campaign; ARQT Falls 1.72%

Arcutis Biotherapeutics (ARQT) announced on September 29, 2026, that gymnast Simone Biles has partnered with the company to launch the "Skin to Believe In" awareness campaign targeting seborrheic dermatitis and eczema. Biles said she uses ZORYVE (roflumilast) foam for seborrheic dermatitis and ZORYVE cream for eczema. ZORYVE is a topical PDE4 inhibitor. The 0.3% foam is approved for seborrheic dermatitis in patients aged 9 and older, while the 0.15% cream is approved for mild to moderate atopic dermatitis in patients aged 6 and older. In trials, 77% of patients on ZORYVE foam achieved clear or almost clear skin at eight weeks versus 53% on inactive foam. For the cream, 31% reached that endpoint at four weeks versus 14% on inactive cream. ARQT traded between $18.62 and $31.77 over the past year and was recently at $26.86, down 1.72%.